JPRN-jRCT2080223370已完成3 期
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Males and Females at least 18 years of age
- •Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery
- •ECOG Performance status of 0 or 1
- •Available tumor sample for testing
- •Acceptable blood work
排除标准
- •Primitive peritoneal, pericardial and tunica vaginalis testis mesotheliomas
- •Prior chemotherapy for pleural mesothelioma
- •Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 oranti-CTLA-4 antibody
- •History of other malignancy unless the subject has been disease-free for at least 3 years
- •Active, untreated central nervous system (CNS) metastasis
研究者
相似试验
进行中（未招募）
1 期
A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA)Stage IV Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 20.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001195-35-ESBristol-Myers Squibb International Corporation504
进行中（未招募）
1 期
A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA)Stage IV Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 20.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001195-35-FRBristol-Myers Squibb International Corporation504
已完成
3 期
CheckMate 816: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 816on-Small Cell Lung CancerJPRN-jRCT2080223597Bristol-Myers Squibb K.K.642
招募中
Unknown
Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational StudyJPRN-UMIN000049936Graduate School of Medicine, Osaka University450
进行中（未招募）
1 期
PHASE 2 CLINICAL STUDY OF NIVOLUMAB COMBINED WITHIPILIMUMAB IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA. (NIVOLUMAB-IPILIMUMAB AT 1MG/KG – NIVOIPI01)EUCTR2016-000742-61-ITAZIENDA OSPEDALIERO-UNIVERSITARIA PISANA60